Citigroup’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-86
| Closed | -$2K | – | 6488 |
|
|
2022
Q2 | $2K | Sell |
86
-9
| -9% | -$201 | ﹤0.01% | 5947 |
|
|
2022
Q1 | $3K | Sell |
95
-469
| -83% | -$17.1K | ﹤0.01% | 6012 |
|
|
2021
Q4 | $26K | Buy |
564
+307
| +119% | +$20.7K | ﹤0.01% | 5325 |
|
|
2021
Q3 | $21K | Buy |
257
+152
| +145% | +$12.6K | ﹤0.01% | 5227 |
|
|
2021
Q2 | $10K | Sell |
105
-300
| -74% | -$35.6K | ﹤0.01% | 5683 |
|
|
2021
Q1 | $67K | Buy |
+405
| New | +$53.6K | ﹤0.01% | 4555 |
|
|
2019
Q4 | – | Sell |
-4
| Closed | – | – | 7844 |
|
|
2019
Q3 | $0 | Sell |
4
-1
| -20% | -$102 | ﹤0.01% | 7854 |
|
|
2019
Q2 | $1K | Sell |
5
-5
| -50% | -$772 | ﹤0.01% | 7700 |
|
|
2019
Q1 | $2K | Hold |
10
| – | – | ﹤0.01% | 7547 |
|
|
2018
Q4 | $1K | Sell |
10
-1
| -9% | -$200 | ﹤0.01% | 7612 |
|
|
2018
Q3 | $2K | Buy |
11
+6
| +120% | +$14.4K | ﹤0.01% | 7626 |
|
|
2018
Q2 | $11K | Buy |
5
+4
| +400% | +$10.1K | ﹤0.01% | 7164 |
|
|
2018
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 7483 |
|
|
2017
Q4 | $1K | Hold |
1
| – | – | ﹤0.01% | 7506 |
|
|
2017
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 7172 |
|
|
2017
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 7527 |
|
|
2017
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7378 |
|
|
2016
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7363 |
|
|
2016
Q3 | $1K | Sell |
1
-3
| -75% | -$2.62K | ﹤0.01% | 7004 |
|
|
2016
Q2 | $3K | Hold |
4
| – | – | ﹤0.01% | 6888 |
|
|
2016
Q1 | $3K | Hold |
4
| – | – | ﹤0.01% | 7161 |
|
|
2015
Q4 | $4K | Hold |
4
| – | – | ﹤0.01% | 7135 |
|
|
2015
Q3 | $4K | Sell |
4
-1
| -20% | -$1.46K | ﹤0.01% | 6852 |
|
|
2015
Q2 | $9K | Hold |
5
| – | – | ﹤0.01% | 6531 |
|
|
2015
Q1 | $4K | Sell |
5
-4
| -44% | -$3.98K | ﹤0.01% | 6807 |
|
|
2014
Q4 | $9K | Buy |
9
+3
| +50% | +$2.68K | ﹤0.01% | 6517 |
|
|
2014
Q3 | $6K | Sell |
6
-2
| -25% | -$2.95K | ﹤0.01% | 6515 |
|
|
2014
Q2 | $15K | Sell |
8
-2
| -20% | -$3.96K | ﹤0.01% | 5972 |
|
|
2014
Q1 | $21K | Sell |
10
-7
| -41% | -$17.4K | ﹤0.01% | 6003 |
|
|
2013
Q4 | $40K | Sell |
17
-1
| -6% | -$2.29K | ﹤0.01% | 5824 |
|
|
2013
Q3 | $51K | Buy |
+18
| New | +$89.6K | ﹤0.01% | 5276 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 6543 |
|
Other funds holding ONCT
QPW
BC
BJL
Citigroup's ONCT Position: Q3 2022 in Review
Citigroup sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 86 shares — an estimated $2K sold.
Citigroup first reported a position in ONCT in Q3 2013 and held it in 31 quarters. The position peaked at $67K in Q1 2021. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.
- Citigroup reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Citigroup sold 86 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2K.
- Citigroup first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2013 and held it in 31 quarters.
- Citigroup's Oncternal Therapeutics, Inc. Common Stock position peaked at $67K in Q1 2021.
- 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.